secwatch.observer — SEC 8-K summary
======================================

Issuer:     Tonix Pharmaceuticals Holding Corp. (TNXP)
CIK:        0001430306
Form:       8-K
Filed at:   2023-12-21T23:59:59+00:00
Accession:  0001999371-23-001135
Event type: other_material
Sentiment:  neutral
Materiality: 0.75
Item codes: 1.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Tonix Pharmaceuticals raises up to $144M in registered direct offering
----------------------------------------------------------------------

- Upfront $30M from sale of ~54M shares/pre-funded warrants at $0.555/share; up to $144M total with warrant exercise.
- Series C warrants (2-yr term, $0.555 strike) and Series D warrants (5-yr term, $0.85 strike) exercisable only after shareholder approval.
- Proceeds for NDA preparation for TNX-102 SL in fibromyalgia and working capital; closing expected Dec 22, 2023.
- A.G.P./Alliance Global Partners placement agent; 45-day lock-up for insiders; 90-day restriction on future equity issuance.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1430306/000199937123001135/0001999371-23-001135-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1430306/000199937123001135/tnxp_8k-122023.htm
  HTML page:      https://secwatch.observer/filing/0001999371-23-001135

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer